Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC

摘要: Abstract Introduction Systemic treatment with chemotherapy is warranted for patients extensive-stage SCLC (ES-SCLC). The objective of this study was to determine whether racial and other healthcare disparities exist in receipt ES-SCLC. Methods Utilizing the National Cancer Database, 148,961 diagnosed have stage IV from 2004 2016 were identified. Adjusted ORs 95% confidence intervals (95% CIs) computed using multivariate logistic regression modeling. Cox modeling used perform overall survival analysis, adjusted hazard ratios calculated. Results A total 82,592 included, among which not administered 6557 (7.9%). Higher education, recent year diagnosis, at more than one facility associated increased odds receiving chemotherapy. Factors a decreased likelihood increasing age, race, nonprivate insurance, comorbidities. On black had lower compared white (adjusted OR, 0.85; CI: 0.77–0.93, p = 0.0004). Furthermore, better ratio, 0.91; 0.89–0.94, 0.91). 1-year (median survival) 31.7% (8.3 mo) 28.6% (8 mo), respectively. Conclusions Black ES-SCLC less likely receive chemotherapy, as elderly, uninsured, those insurance. Further studies are required address underlying reasons lack guide appropriate interventions mitigate disparities.